NeurAxis (NRXS) said Monday it received a new 510(k) clearance from the US Food and Drug Administration for its IB-Stim nerve stimulator for functional abdominal pain relief, expanding its indication for use in people between 8 and 21 years of age from a previous indication for 11- to 18-year olds.
IB-Stim is a non-surgical device that sends "gentle" electrical impulses into cranial nerve bundles in the ear, the medical technology company said.
Price: 2.26, Change: -0.33, Percent Change: -12.74
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。